CRMD
Biotechnology · Healthcare
Analyst
LifeSci Advisors
Head of Investor Relations
Praxis Precision Medicines, Inc. (PRAX)Equibles does not estimate personal net worth.
Daniel Ferry is recorded as Analyst at LifeSci Advisors and Head of Investor Relations at Praxis Precision Medicines, Inc. (PRAX). Daniel Ferry has spoken on 12 earnings calls across 4 companies, most recently for Praxis Precision Medicines, Inc. on August 6, 2026. Those appearances were for CorMedix Inc. (CRMD), X4 Pharmaceuticals, Inc (XFOR), Praxis Precision Medicines, Inc. (PRAX) and Mineralys Therapeutics, Inc. (MLYS). CorMedix Inc. is classified in the Biotechnology industry within the Healthcare sector. Praxis Precision Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Daniel Ferry spoke on are classified in the Healthcare sector. Other leadership on record at CorMedix Inc. includes Joseph Todisco (CEO, Chairman and Board Member), Matt David, M.D. (CEO), Matthew David, M.D. (CEO) and 7 others.
“Good morning, and welcome to the Praxis Precision Medicine's second quarter 2026 financial results and business update conference call.”
“Good morning, and welcome to the CorMedix First Quarter 2026 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chairman and Chief Executive Officer of CorMedix.”
“Good morning, and welcome to the CorMedix Third Quarter 2025 Earnings and Corporate Update Conference Call. Leading the call today is Joe Todisco, Chief Executive Officer of CorMedix; and he is joined by Liz Hurlburt, EVP and Chief Operating Officer; and Susan Blum, EVP and Chief Financial Officer.”
“I would like to welcome everyone joining us today for our third quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our third quarter 2025 financial results and business updates.”
“Thank you for joining us today for the special earnings call during which X4 will focus on providing a business update and, importantly, data and results from its now completed Phase II study of mavorixafor in chronic neutropenia.”
LifeSci Advisors
Analyst
Source not stated
Source not stated
CRMD
Biotechnology · Healthcare
Biotechnology · Healthcare
Head of Investor Relations